Reassessment of renal prognosis in patients with membranoproliferative glomerulonephritis according to the new pathologic classification

DOI: https://doi.org/10.31450/ukrjnd.4(68).2020.04
Keywords: membranoproliferative glomerulonephritis, classification, treatment, kidney outcomes.

Abstract

Membranoproliferative glomerulonephritis (MPGN) is a heterogeneous disease characterized by a morphological injury pattern that can be seen under various disease conditions that share common pathogenic mechanisms. In this study, we analyzed clinical features, pathological findings, long-term kidney outcomes according to the new pathohistological classification of MPGN.

Methods. This retrospective study included 20 CKD patients with biopsy-proven MPGN that had been diagnosed between 2011 and 2019. We reclassified the patterns of MPGN as immune-complexes mediated (ICM) and complement-mediated (CM) according to the new classification.

Results. The level of daily proteinuria was lower in the ICM MPGN than the CM MPGN group but was not statistically significant at the end of the study. Histopathologically, the difference in C3 staining was found between the patients with ICM and CM MPGN. At the end of the follow-up period, no patients developed end-stage renal disease, and no death occurred in response to treatment in the ICM MPGN group. In the CM MPGN group, 2 patients evolved to end-stage renal disease and 1 of them had renal transplantation.

Conclusion. Larger sample size and longer follow-up may change the relationship between histological factors, treatment strategies, and kidney outcomes. We believe that the use of the new diagnostic approach that applies to the ICM MPGN and CM MPGN will help nephrologists to improve treatment options and renal outcomes for patients with MPGN.

Downloads

Download data is not yet available.

References

Hohenstein B. C3-Glomerulopathie und MPGN – aktuelle Klassifikationen [C3 glomerulopathy and MPGN - current classification]. Dtsch Med Wochenschr. 2020;145(4):232-239. doi:10.1055/a-0974-8418.

Andrighetto S, Leventhal J, Zaza G, Cravedi P. Complement and Complement Targeting Therapies in Glomerular Diseases. Int J Mol Sci. 2019;20(24):6336. doi: 10.3390/ijms20246336.

Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis – a new look at an old entity. N Engl J Med. 2012; 366: 1119-31. doi: 10.1056/NEJMra1108178.

Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol. 2011; 31: 341-348. doi: 10.1016/j.semnephrol.2011.06.005.

Bomback AS, Appel GB. Pathogenesis of the C3 glomerulopathies and reclassification of MPGN. Nat Rev Nephrol. 2012;8(11):634–42. doi: 10.1038/nrneph.2012.213.

Sethi S, Nester CM, Smith RJ. Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion. Kidney Int. 2012; 81: 434-41. doi: 10.1038/ki.2011.399.

D’Agati VD, Bomback AS. C3 glomerulopathy: what’s in a name? Kidney Int. 2012; 82: 379-81. doi: 10.1038/ki.2012.80.

Cook HT, Pickering MC. Clusters not classifications: making sense of complement-mediated kidney injury. J Am Soc Nephrol. 2018;29(1):9-12. doi: 10.1681/ASN.2017111183.

Santos JE, Fiel D, Santos R, et al. Rituximab use in adult glomerulopathies and its rationale. J Bras Nefrol. 2020;42(1):77-93. doi:10.1590/2175-8239-JBN-2018-0254.

Sethi S, Fervenza FC, Zhang Y, Zand L, Meyer NC, Borsa N, Nasr SH, Smith RJ. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int. 2013; 83: 293-299. doi: 10.1038/ki.2012.384.

Viswanathan GK, Nada R, Kumar A, et al. Clinico-pathologic spectrum of C3 glomerulopathy – an Indian experience. Diagn Pathol. 2015;10:6. doi: 10.1186/s13000-015-0233-0.

Himamani S. Membranoproliferative glomerulonephritis common glomerular disease – changing pattern of biopsy proven renal disease in a Tertiary Care Hospital. Int J Sci Stud.2016;3(11):193-6. Available from: https://www.semanticscholar.org/paper/Membranoproliferative-Glomerulo-Nephritis-Common-of-Himamani/a89017f20e4cb4e7afed56652a3d74317f15a720#paper-header.

Servais A, Noël LH, Roumenina LT, Le Quintrec M, Ngo S. et al. Acquired and genetic complement abnormalities play a criticalrole in dense deposit disease and other C3 glomerulopathies. Kidney Int. 2012;82(4):454–64. doi: 10.1038/ki.2012.63.

Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int. 2018;93(4):977–85. doi: 10.1016/j.kint.2017.10.022.

Nakano M, Karasawa K. et al. Characteristics of membranoproliferative glomerulonephritis based on a new classification at a single center.Clin Exp Nephrol. 2019 Jun;23(6):852-58. doi: 10.1007/s10157-019-01716-7.

Morales JM, Kamar N, Rostaing L. Hepatitis C and renal disease: epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol. 2012;176:10-23. doi: 10.1159/000333772.

Nargund P, Kambham N. et al. Clinicopathological features of membranoproliferative glomerulonephritis under a new classification. Clinical Nephrology, 2015; Vol. 84, No. 6:323-30. doi: 10.5414/CN108619.

Corvillo F, Okrój M, Nozal P, Melgosa M, Sánchez-Corral P, López-Trascasa M. Nephritic Factors: An Overview of Classification, Diagnostic Tools and Clinical Associations. Front Immunol. 2019;10:886. doi: 10.3389/fimmu.2019.00886.

Imtiaz S, Dhrolia MF, Nasir K, Salman B, Ahmad A. Type of immune and complement deposits and response of immunosuppressive treatment on membranoproliferative glomerulonephritis - a single centre experience. J Pak Med Assoc.2015;65(9):995-1000. Available from: https://pubmed.ncbi.nlm.nih.gov/26338748/.

Iatropoulos P, Daina E, Curreri M, Piras R, Valoti E, et al. Registry of membranoproliferative glomerulonephritis/C3 glomerulopathy; Nastasi. Cluster analysis identifies distinct pathogenetic patterns in C3 glomerulopathies/immune complex-mediated membranoproliferative GN. J Am Soc Nephrol. 2018;29(1):283–94. doi: 10.1681/ASN.2017030258.

Deshpande N, Tewari C, Badwal C, et all. Evaluation of cases of membranoproliferative glomerulonephritis according to newer classification: A retrospective record-based study. Med J Armed Forces India. 2018;74: 264-7. doi: 10.1016/j.mjafi.2017.01.008.

Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol. 2012;7:748-56. doi: 10.2215/CJN.12901211.


Abstract views: 494
PDF Downloads: 15980
Published
2020-10-19
How to Cite
Parmaksız, E., & Meşe, M. (2020). Reassessment of renal prognosis in patients with membranoproliferative glomerulonephritis according to the new pathologic classification. Ukrainian Journal of Nephrology and Dialysis, (4(68), 23-28. https://doi.org/10.31450/ukrjnd.4(68).2020.04
Issue
No 4(68) (2020): Ukrainian Journal of Nephrology and Dialysis
Section
Original Papers